Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Constellation heading for pivotal myelofibrosis trial as ASH data lifts shares

November 7, 2019 1:04 AM UTC

Constellation's shares nearly doubled in value Tuesday after the company reported Phase II data showing CPI-0610 plus SOC Jakavi could improve response rates for myelofibrosis patients, along with plans to launch Phase III testing of the therapy next year.

The data from the Phase II MANIFEST study were released in abstracts ahead of the American Society of Hematology (ASH) meeting in December. Constellation Pharmaceuticals Inc. (NASDAQ:CNST) gained $13.33 (90%) to $28.10 on the day. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article